1,938 reports of this reaction
12.4% of all ACALABRUTINIB reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for ACALABRUTINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,938 FDA adverse event reports linking ACALABRUTINIB to DEATH. This represents approximately 12.4% of all 15,655 adverse event reports for this drug.
Patients taking ACALABRUTINIB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is a frequently reported adverse event for ACALABRUTINIB, accounting for a significant proportion of all reports.
In addition to death, the following adverse reactions have been reported for ACALABRUTINIB:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 1,938 FDA reports for ACALABRUTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 12.4% of all adverse event reports for ACALABRUTINIB, making it one of the most commonly reported side effect.
If you experience death while taking ACALABRUTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.